The increasing life expectancy of our population will mean that by the year 2000 we may expect a large number of women to be in age groups at significant risk for malignancies of the female reproductive tract. It is very unlikely that we will soon understand the cause of cancer, and effective new therapies are not to be anticipated. Rather, improved survival and diminished morbidity must be obtained by insuring ready and equal access to state of the art treatment, for the patient and physician.